Oleamide derivatives are prototypical anti-metastasis drugs that act by inhibiting connexin 26

Current Drug Safety

Volumn 2, Issue 3, 2007, Pages 204-211

  Nojima, Hiroshi ^a   Ohba, Yusuke ^b   Kita, Yasuyuki ^b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

BL6; Connexin 26; Gap junction; Hemichannel; Metastasis; Oleamide

Indexed keywords

ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; CONNEXIN 26; CONNEXIN 32; CONNEXIN 43; MI 18; MI 22; OLEAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RESEARCH; CELL COMMUNICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GAP JUNCTION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; METASTASIS INHIBITION; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CONNEXINS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; OLEIC ACIDS; PROGNOSIS;

EID: 35348856861     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607781668837     Document Type: Review

References (67)

1. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
2. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005; 5: 355-366.
3. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-695.
4. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002; 12: 89-96.
5. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20: 2149-2182.
6. Chin L. The genetics of malignant melanoma: Lessons from mouse and man. Nat Rev Cancer 2003; 3: 559-570.
7. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005; 307: 1904-1909.
8. McLachlan RW, Yap AS. Not so simple: the complexity of phosphotyrosine signaling at cadherin adhesive contacts. J Mol Med 2007, in press.
9. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-826.
10. Nam JS, Hirohashi S, Wakefield LM. Dysadherin: A new player in cancer progression. Cancer Lett 2007, in press.
11. Fidler IJ. Models for spontaneous metastasis. Cancer Res 2006; 66: 9787.
12. Poste G, Doll J, Hart IR, Fidler IJ. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 1980; 40: 1636-1644.
13. Morikawa K, Walker SM, Jessup JM, Fidler IJ. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 1988; 48: 1943-1948.
14. Naito S, Walker SM, Fidler IJ. In vivo selection of human renal cell carcinoma cell with high metastatic potential in nude mice. Clin Exp Metastasis 1989; 7: 381-389.
15. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Ridler U. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation, in nude mice. Neoplasia 1999; 1: 50-62.
16. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973; 242: 148-149.
17. Weiss L. Comments on 'In vivo selection of human renal carcinoma cells with high metastatic potenital in nude mice'. Clin Exp Metastasis 1990; 8: 103-109.
18. Fujii T, Tamura K, Masai K, Tanaka H, Nishimune, Y, Nojima H. Use of stepwise subtraction to comprehensively isolate mouse genes whose transcription is up-regulated during spermiogenesis. EMBO Rep 2002; 3: 367-372.
19. Kataoka TR, Ito A, Asada H, et al. Annexin VII as a novel marker for invasive phenotype of malignant melanoma. Jpn J Cancer Res 2000; 91: 75-83.
20. Nakaji T, Kataoka TR, Watabe K, et al. A new member of the GTPase superfamily that is upregulated in highly metastatic cells. Cancer Lett 1999; 147: 139-147.
21. Ito A, Katoh F,, Kataoka TR, et al. A role for heterologous gap junctions between melanoma and endothelial cells in metastasis. J Clin Invest 2000; 105: 1189-1197.
22. Ito A, Kataoka TR, Watanabe M, et al. A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation. EMBO J 2000; 19: 562-571.
23. Watabe K. Ito A, Asada H, et al. Structure, expression and chromosome mapping of MLZE, a novel gene which is preferentially expressed in metastatic melanoma cells. Jpn J Cancer Res 2001; 92: 140-151.
24. Nakamoto Y, Ito A, Watabe K. et al. Increased expression of a nucleolar Nop5/Sik family member in metastatic melanoma cells: evidence for its role in nucleolar sizing and function. Am J Pathol 2001; 159(4): 1363-74.
25. Mesnil M. Crespin S, Avanzo JL, Zaidan-Dagli ML. Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 2005; 1719: 125-145.
26. Cruciani V, Mikalsen SO. The vertebrate connexin family. Cell Mol Life Sci 2006; 63: 1125-1140.
27. Laird DW. Life cycle of connexins in health and disease. Biochem J 2006; 394: 527-543.
28. Liu F, Arce FT, Ramachandran S, Lal R. Nanomechanics of hemichannel conformations: connexin flexibility underlying channel opening and closing. J Biol Chem 2006; 281: 23207-23217.
29. Omori Y, Zaidan Dagli ML, Yamakage K, Yamasaki H. Involvement of gap junctions in tumor suppression: analysis of genetically-manipulated mice. Mutat Res 2001; 477: 191-196.
30. Chen Y, Huhn D, Knosel T, Pacyna-Gengelbach M, Deutschmann N, Petersen I. Downregulation of connexin 26 in human lung cancer is related to promoter methylation. Int J Cancer 2005; 113(1): 14-2l.
31. Tan LW, Bianco T, Dobrovic A. Variable promoter region CpG island methylation of the putative tumor suppressor gene Connexin 26 in breast cancer. Carcinogenesis 2002; 23: 231-236.
32. Asamoto M, Takahashi S, Imaida K, Shirai T, Fukushima S. Increased gap junctional intercellular communication capacity and connexin 43 and 26 expression in rat bladder carcinogenesis. Carcinogenesis 1994; 15: 2163-2166.
33. Budunova IV, Carbajal S, Viaje A, Slaga TJ. Connexin expression in epidermal cell lines from SENCAR mouse skin tumors. Mol Carcinog 1996; 15: 190-201.
34. Jamieson S, Going JJ, D'Arcy R, George WD. Expression of gap junction proteins connexin 26 and connexin 43 in normal human breast and in breast tumours. J Pathol 1998; 184: 37-43.
35. Saunders MM, Seraj MJ, Li Z, et al. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 2001; 61: 1765-1767.
36. Kapoor P, Saunders MM, Li Z, et al. Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. Int J Cancer 2004; 111: 693-697.
37. Saito-Katsuragi M, Asada, H, Kitamura K, et al. A role for connexin 26 in metastasis of human malignant melanoma: communication between melanoma and endothelial cells via connexin 26. Cancer 2007; in press.
38. Tate AW, Lung T, Radhakrishnan A, Lim SD, Lin X, Edlund M. Changes in gap junctional connexin isoforms during prostate cancer progression. Prostate 2006; 66: 19-31.
39. Ito A, Koma YI, Uchino K, et al. Increased expression of connexin 26 in the invasive component of lung squamous cell carcinoma: Significant correlation with poor prognosis. Cancer Lett 2006; 234: 239-248.
40. Bry C; Maass K, Miyoshi K, et al. Loss of connexin 26 in mammary epithelium during early but not during late pregnancy results in unscheduled apoptosis and impaired development. Dev Biol 2004; 267: 418-429.
41. Haass NK, Wladykowski E, Kief S, Moll I, Brandner JM. Differential induction of connexins 26 and 30 in skin tumors and their adjacent epidermis. J Histochem Cytochem 2006; 54: 171-182.
42. Kanczuga-Koda L, Sulkowski S, Lenczewski A, et al. Increased expression of connexins 26 and 43 in lymph node metastases of breast cancer. J Clin Pathol 2006; 59: 429-433.
43. Muramatsu A, Iwai M, Morikawa T, et al. Influence of transfection with connexin 26 gene on malignant potential of human hepatoma cells. Carcinogenesis 2002; 23: 351-358.
44. McLachlan E, Shao Q, Wang HL, Langlois S, Laird DW. Connexins act as tumor suppressors in three-dimensional mammary cell organoids by regulating differentiation and angiogenesis. Cancer Res 2006; 66: 9896-9894.
45. Boger DL, Henriksen SJ, Cravatt BF. Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Curr Pharm Des 1998; 4: 303-314.
46. Fowler CJ. Oleamide: a member of the endocannabinoid family? Br J Pharmacol 2004; 141: 195-196.
47. Boger DL, Patterson JE, Guan X, Cravatt BF, Lerner RA, Gilula NB. Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc Natl Acad Sci U S A 1998; 95: 4810-4815.
48. Guan X, Cravatt BF, Ehring GR, et al. The sleep-inducing lipid oleamioe deconvolutes gap junction communication and calcium wave transmission in glial cells. J Cell Biol 1997; 139: 1785-1792.
49. Gutstein DE, Morley GE, Tamaddon H, et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 2001; 88: 333-339.
50. Ohba Y, Kanao Y, Morita N, et al. Oleamide derivatives suppress the spontaneous metastasis by inhibiting connexin 26. Int J Cancer 2007; 121: 2801-2808.
51. Miura D, Kida Y, Nojima H. Camellia oil and its distillate fractions effectively inhibit the spontaneous, metastasis of mouse melanoma BL6 cells. FEBS Lett 2007; in press.
52. Saez JC, Retamal MA, Basilio D, Bukauskas FF, Bennett MV. Connexin-based gap junction hemichannels: gating, mechanisms. Biochim Biophys Acta 2005; 1711: 215-224.
53. Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol 2003; 4: 285-294.
54. Spray DC, Ye ZC, Ransom BR. Functional connexin "hemichannels": a critical appraisal. Glia 2006; 54: 758-773.
55. Koval M. Pathways and control of connexin oligomerization. Trends Cell Biol 2006; 16: 159-166.
56. Bruzzone S, Franco L, Guida L, et al. A self-restricted CD38-connexin 43 cross-talk affects NAD+ and cyclic ADP-ribose metabolism and regulates intracellular calcium in 3T3 fibroblasts. J Biol Chem 2001: 276: 48300-48308.
57. Li H, Brodsky S, Kumari S, et al. Paradoxical overexpression and translocation of connexin43 in homocysteine-treated endothelial cells. Am J Physiol Heart Circ Physiol 2002; 282: 2124-2133.
58. Boengler K, Dodoni G, Rodriguez-Sinovas A, et al. Connexin 43 in cardiomyocyte mitochondria and its-increase by ischemic preconditioning. Cardiovasc Res 2005; 67: 234-244.
59. Rodriguez-Sinovas A, Boengler K, Cabestrero A, et al. Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM-pathway and its importance for cardioprotection. Circ Res 2006; 99: 93-101.
60. Goubaeva F, Mikami M, Giardina S, Ding B, Abe J, Yang J. Cardiac mitochondrial connexin 43 regulates apoptosis. Biochem Biophys Res Commun 2007; 352: 97-103.
61. Govindarajan R, Zhao S, Song XH, et al. Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by alpha-catenin. J Biol Chem 2002; 277: 50087-50097.
62. Kanczuga-Koda L, Sulkowski S, Koda M, Skrzydlewska E, Sulkowska M. Connexin 26 correlates with Bcl-xL and Bax proteins expression in colorectal cancer. World J Gastroenterol 2005; 11: 1544-1548.
63. Krutovskikh V, Mazzoleni G, Mironov. N, et al. Altered homologous and heterologous gap-junctional intercellular communication in primary human liver tumors associated with aberrant protein localization but not gene mutation of connexin 32. Int J Cancer 1994; 56(1): 87-94.
64. Tanaka M, Grossman HB. Connexin 26 induces growth-suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. Oncol Rep 2004; 11: 537-541.
65. Brehm R, Marks A, Rey R, Kliesch S, Bergmann M, Steger K. Altered expression of connexins 26 and 43 in Sertoli cells in seminiferous tubules infiltrated with carcinoma-in-situ or seminoma. J Pathol 2002; 197: 647-653.
66. Ohba Y, Kanao Y, Takatsuji M, et al. Synthesis of N-functional oleamide derivatives. Tetrahedron 2007, in press.
67. Ito A, Morita N, Miura D, et al. A derivative of oleamide potently inhibits the spontaneous metastasis of mouse melanoma BL6 cells. Carcinogenesis 2004; 25: 2015-2022.